Yes—Perform FNA Now for This Growing Thyroid Nodule
A thyroid nodule that has enlarged from 1.3 × 0.9 × 0.9 cm to 2 × 1.65 × 1.25 cm over 10 years represents significant growth (≥3 mm threshold exceeded by 5–6 fold) and now exceeds 2 cm, mandating ultrasound-guided fine-needle aspiration regardless of sonographic features. 1
Why This Nodule Requires Immediate FNA
Size-Based Indications
Any thyroid nodule ≥2 cm warrants FNA evaluation even without suspicious ultrasound features, because size alone increases malignancy risk. 1
The current nodule measures 2 cm in maximal diameter, which crosses the threshold where the American College of Surgeons and National Comprehensive Cancer Network recommend evaluation due to increased cancer risk. 1
Nodules ≥4 cm have higher false-negative FNA rates (though still acceptable at 7.1%), but your 2 cm nodule falls within the optimal diagnostic range where FNA sensitivity reaches 81.6% and negative predictive value is 93.7%. 2
Growth-Based Indications
Growth of ≥3 mm in any dimension during surveillance is the established threshold for significant progression requiring cytological evaluation. 3
Your nodule has grown approximately 7 mm in the longest dimension and 7.5 mm in another dimension—representing 5–6 times the threshold for clinically significant enlargement. 1
Rapid growth is one of the strongest independent predictors of malignancy, far outweighing baseline size considerations; only 8% of papillary microcarcinomas enlarge by ≥3 mm over 10 years, making this degree of growth highly atypical for benign disease. 1
The 10-year timeframe with documented progressive enlargement distinguishes this from measurement variability (which accounts for changes <1.7 mm); your 14–17 mm growth far exceeds any measurement error margin. 1
Critical Ultrasound Assessment Required Before FNA
High-Risk Sonographic Features to Document
When performing the pre-FNA ultrasound, specifically assess for:
Marked hypoechogenicity (solid nodule darker than surrounding thyroid parenchyma; positive predictive value 1.85 for malignancy) 1, 4
Microcalcifications (hyperechoic spots ≤1 mm representing psammoma bodies; PPV 3.65, highly specific for papillary thyroid carcinoma) 1, 4
Irregular or microlobulated margins (infiltrative borders rather than smooth contours; PPV 3.76) 1, 4
Absence of peripheral halo (loss of thin hypoechoic rim normally surrounding benign nodules) 1
Solid composition (higher malignancy risk than cystic nodules) 1
Central hypervascularity (chaotic internal vascular pattern versus peripheral-only flow) 1
Cervical Lymph Node Evaluation
Perform comprehensive neck ultrasound assessing both central and lateral cervical lymph node basins for suspicious features including loss of fatty hilum, microcalcifications, cystic change, or abnormal vascularity. 1
Suspicious cervical lymphadenopathy is an absolute indication for FNA regardless of nodule size. 1
Procedural Approach
FNA Technique
Ultrasound-guided FNA is mandatory (not palpation-guided) because it provides real-time needle visualization, confirms accurate sampling of the solid component, enables marker clip placement if needed, and is superior in accuracy, patient comfort, and cost-effectiveness. 1
Target the solid portion if the nodule has any cystic components, as the solid component carries the highest malignancy risk. 1
Ensure adequate sampling to minimize the 5–20% rate of initially inadequate specimens; if nondiagnostic, repeat ultrasound-guided FNA is mandatory. 1
Additional Diagnostic Testing
Measure serum calcitonin as part of the diagnostic workup to screen for medullary thyroid cancer, which has higher sensitivity than FNA alone (detects 5–7% of thyroid cancers that FNA may miss). 1
Measure TSH levels to determine if the nodule is autonomously functioning; if TSH is suppressed with elevated T4, proceed to thyroid scintigraphy—a "hot" nodule would favor medical management (radioactive iodine) over surgery and FNA would not be indicated. 1
Management Based on FNA Results
Bethesda II (Benign): Malignancy Risk 1–3%
Continue surveillance with repeat ultrasound at 12–24 months to monitor for interval growth or development of suspicious features. 1
Do not override a benign FNA if worrisome clinical findings persist, as false-negative results occur in up to 11–33% of cases; consider repeat FNA or surgical consultation if clinical suspicion remains high. 1
Bethesda III (Atypia/Follicular Lesion of Undetermined Significance): Malignancy Risk 10–30%
Repeat ultrasound-guided FNA is the standard first step, yielding a more definitive diagnosis in 42–62% of cases. 5
Consider molecular testing (BRAF, RAS, RET/PTC, PAX8/PPARγ) to refine malignancy risk; 97% of mutation-positive nodules are malignant. 1
Proceed directly to diagnostic lobectomy if nodule size ≥4 cm or if high-risk clinical factors are present (age <30 years, history of head/neck radiation, family history of thyroid cancer, rapidly growing nodule, suspicious lymphadenopathy). 5
Bethesda IV (Follicular Neoplasm): Malignancy Risk 25–40%
Surgical excision is required for definitive diagnosis, as FNA cannot distinguish follicular adenoma from carcinoma. 1
Diagnostic lobectomy is the standard approach; completion thyroidectomy is performed only if final histology confirms malignancy with high-risk features. 1
Bethesda V (Suspicious) or VI (Malignant): Malignancy Risk 50–75% and 97–99%
Immediate referral to an endocrine surgeon for total or near-total thyroidectomy with pre-operative assessment of lymph node compartments. 1
Surgical consultation should be arranged within 2–4 weeks of the pathology report to minimize treatment delays. 1
Compartment-oriented lymph node dissection is indicated when lymph node metastases are suspected preoperatively or proven intraoperatively. 1
Common Pitfalls to Avoid
Do Not Delay FNA Based on Benign Appearance
Palpation cannot reliably differentiate benign from malignant thyroid nodules; a solid, firm, mobile, non-tender nodule does not exclude cancer. 1
Most thyroid cancers occur in patients with normal thyroid function; TSH testing and radionuclide scanning in euthyroid patients do not substitute for FNA. 1
Do Not Rely on Short-Term Observation
- Observation for 4–6 weeks is appropriate only for suspected infectious/inflammatory conditions or post-procedural changes—not for solid thyroid nodules with documented growth over 10 years. 1
Do Not Assume Benign Disease Based on Slow Growth
- While most benign nodules remain stable or grow slowly, the combination of size >2 cm plus documented growth >3 mm is an independent risk factor that overrides the reassurance of a 10-year timeframe. 1
Age-Related Risk Considerations
If the patient is younger than 40 years, this represents an independent predictor of papillary microcarcinoma progression in multivariate analysis; younger patients have higher progression rates in active-surveillance cohorts. 3, 1
Conversely, low-risk papillary microcarcinomas in elderly patients are less likely to grow than those in young and middle-aged patients, but this nodule's size (2 cm) exceeds the microcarcinoma definition (<1 cm). 3
Why Repeat FNA After 10 Years Is Justified
Evidence Supporting Repeat FNA in Growing Nodules
Repeat FNA is indicated when nodule size increases, as this represents a change in clinical status that may reflect malignant transformation or sampling error in the initial benign diagnosis. 6, 7
In one study of 799 aspirations over 2–12 years, 4 patients (1.30%) had diagnosis changed to papillary carcinoma on repeat FNA—1 diagnosed on second FNA (0.57%) and 3 on third FNA (2.25%). 6
Three of the carcinomas found showed no changes in size, emphasizing that growth is not the only indication for repeat FNA, but when present, it is a strong indication. 6
Limitations of Routine Repeat FNA Without Growth
Routine repeat FNA in benign nodules without clinical changes has limited usefulness; one study of 94 re-aspirations detected no malignant neoplasms in nodules without size change. 7
However, your nodule has demonstrated significant growth, which distinguishes it from the stable nodules in these studies and justifies repeat evaluation. 7
Summary Algorithm
Perform high-resolution ultrasound documenting nodule size, composition, echogenicity, margins, calcifications, vascularity, and cervical lymph nodes. 1
Measure serum TSH and calcitonin. 1
If TSH is normal or elevated, proceed directly to ultrasound-guided FNA of the solid component. 1
If TSH is suppressed, obtain thyroid scintigraphy; if "hot," consider radioactive iodine therapy instead of FNA. 1
Manage based on Bethesda classification as outlined above, with surgical consultation for Bethesda III–VI results. 1, 5
If Bethesda II (benign), continue surveillance but maintain high clinical suspicion given the documented growth; consider repeat FNA at 12 months if any suspicious features develop. 1